AX-2024-005086 · IGF-1 DES (1-3) · SSA lot SSA-2403-F6772

Section 1

Results

Measured against the index acceptance specification for the growth-hormone axis peptides class. A specification is a decision the index made; a result is a measurement. See where each threshold came from.

Parameter	Method	Result	Unit	Index spec
Purity	RP-HPLC, 25 min gradient, 214 nm	99.53	% area	≥ 95.0	PASS
Total impurities	RP-HPLC, sum of reported peaks	0.47	% area	≤ 5.0	PASS
Largest single impurity	RP-HPLC — des(1-4) over-truncate (−87 Da)	0.32	% area	≤ 1.00	PASS
Identity — theoretical monoisotopic mass	calculated from molecular formula	7365.7188	Da	—	NOT TESTED
Identity — observed monoisotopic mass	LC-MS, unit resolution (single quadrupole)	7365.7785	Da	—	NOT TESTED
Mass accuracy	observed vs theoretical	+8.1	ppm	± 15	PASS
Peptide content	not ordered on this submission	not determined	—	required to check label claim	NOT TESTED
Water content	Karl Fischer, coulometric, duplicate	3.61	%	≤ 9.0	PASS
Counter-ion (acetate)	anion-exchange ion chromatography	4.70	%	≤ 12.0	PASS
Residual solvent + inorganic residue	estimated — see /methods/residual-solvents-q3c/	0.18	%	—	NOT TESTED
Endotoxin	not ordered on this submission	not determined	—	≤ 5.0	NOT TESTED
Sterility	not ordered on this submission	not determined	—	no growth	NOT TESTED
Appearance	visual, diffuse light, black and white background	White lyophilised cake, intact	—	white to off-white intact cake	PASS
Reconstitution clarity	reconstituted per submitter procedure	Clear, colourless, no visible particulates	—	clear, no visible particulates	PASS
pH (reconstituted, 1 mg/mL)	potentiometric, two-point calibration	5.77	—	2.5 – 8.0	PASS
Retention time (observed)	RP-HPLC, 25 min gradient	13.56	min	13.43 ± 0.50 (normalised)	PASS
Peak asymmetry (10 % height)	Ph. Eur. 2.2.46	1.50	—	0.80 – 1.50	PASS
Plate count, main peak	N = 5.54 (t/w½)²	61,015	—	≥ 20,000	PASS
Resolution to nearest impurity	vs des(1-4) over-truncate (−87 Da)	1.33	—	no index criterion	REPORTED

Section 2

Chromatogram and peak integration

The figure is drawn from the table. It is not an independent illustration — if a number in the table changed, the trace would change with it.

Figure 1. RP-HPLC trace, 25 min gradient, 214 nm. Drawn from the peak-integration table below: peak positions are the reported retention times, peak areas are the reported area percentages, peak widths follow the reported plate count of 61,015, and skew follows the reported asymmetry factor of 1.50. Baseline noise is seeded from the report ID and is illustrative. The lower panel is the same trace at a stated vertical expansion with the slow gradient drift subtracted, because at full scale a 0.32 % impurity against a 99.53 % main peak is a line two pixels tall; the main peak runs off-scale there by design.

#	Peak	RT	Area (µV·s)	% area	Δ mass (Da)
1	IGF-1 DES (1-3) — main peak	13.56	4,837,467	99.53	—
2	des(1-4) over-truncate (−87 Da)	13.26	15,553	0.32	-87.032
3	disulfide-scrambled isomer	14.04	3,402	0.07	0.000
4	full-length IGF-1 (+343 Da)	13.96	2,430	0.05	+342.166
5	aggregated dimer	16.10	1,458	0.03	+7365.719
Closure check — purity + Σ impurities				100.00	CLOSES

Reporting threshold 0.05 % area. Peaks below it are not reported and are therefore excluded from the total, which overstates purity by their sum — see peak integration.

Section 3

Mass spectrum and identity

Theoretical monoisotopic mass 7365.7188 Da, computed from C317H508N92O95S7. All ppm figures on this site are against monoisotopic values — see why that matters.

Figure 2. ESI charge-state envelope, unit-resolution instrument. Sticks are placed at m/z = (M + z × 1.007276)/z for the observed neutral mass of 7365.7785 Da. Sodium (+21.982/z) and potassium (+37.956/z) adducts are shown where the parent charge state exceeds 25 % relative abundance; they are adducts of the same molecule and are not impurities.

Charge	Theoretical m/z	Observed m/z	Δ m/z	Rel. abundance (%)
9+	819.4205	819.4271	0.0066	8.7
8+	921.7221	921.7296	0.0075	49.7
7+	1053.2528	1053.2613	0.0085	100.0
6+	1228.6271	1228.6370	0.0099	53.9
5+	1474.1510	1474.1630	0.0120	8.0

Section 4

Gravimetric mass balance

Water, counter-ion, residual and total peptide content are exhaustive and mutually exclusive categories. They must account for 100 % of the cake mass. The index closes this to within 0.02 pp and the build asserts it.

Supplier certificate, as declared

The supplier's own figures for this lot, beside the independent measurement. Divergence is assessed against the batch median, not against this single report — see rule AX-R05.

Figure	Supplier COA	This report	Index note
Purity (% area)	99.30	99.53	divergence +0.11 pp vs batch median
Total impurities (% area)	not stated	0.47
Largest single impurity (% area)	not stated	0.32
Water (%)	not stated	3.61
Counter-ion (%)	not stated	4.70
Peptide content (%w/w)	not stated	not determined
Endotoxin (EU/mg)	not stated	not determined
Method stated on certificate	NO	—	no method section — the result cannot be reconciled against any other

Section 5

Provenance and caveats

Where a sample came from changes the weight of the evidence. The index treats it as a first-class field.

Sample provenance: Buyer-sourced
Evidentiary weight: Strongest available evidence in this index.
Chain of custody: Retail purchase → submitter (−20 °C, 13 d) → laboratory (courier, dry ice, 7 d) → assay.
Assay date: 23 Apr 2024
Submitted to the index: 30 Apr 2024
Laboratory: Medutest, Ljubljana, Slovenia
Method basis: 25 min gradient · unit-resolution MS
Verification status: IDENTITY CONSISTENT

What this report does not establish

That the compound is not a near-isobaric alternative. Identity was confirmed at unit mass resolution, which cannot exclude species differing by 1 or 2 Da. The specific alternatives not excluded are named in the identity block above.
How much of the named compound is in the vial. Peptide content was not determined, so recovered mass cannot be calculated and the label claim cannot be checked.
That the material is free of bacterial endotoxin. Endotoxin was not measured. No chromatographic result bears on it.
That the material is sterile. Sterility was not tested.
That the protein is correctly folded. Reverse-phase chromatography measures hydrophobic heterogeneity. A correctly-massed, chromatographically-homogeneous recombinant protein can be entirely mis-paired at its disulfides. Purity here is an upper bound and nothing more.
That any other vial in the same lot has the same composition. One vial was tested. Within-lot vial-to-vial variation in this index has a median of 0.28 pp and a 90th percentile of 0.74 pp.
That any other lot from the same supplier has the same composition. Batch-to-batch variation is larger than within-batch variation for every supplier here.
That the material is suitable for administration to a human or an animal. These are research compounds. No result on this site is a safety assessment and the index takes no position on use.
That the material was manufactured by the supplier that sold it. Contract synthesis is normal in this market and twenty-nine batches in the index fingerprint to a bulk from a different company than the one named on the label.

Section 6

Annotations 3

Signed technical comments from index contributors. Not a discussion forum — annotations question or contextualise the result, and the data team replies where a reply is warranted.

diode_array30 Apr 2024

Photodiode-array spectral homogeneity across the main peak would convert 99.53 % from a good number into a checked one. It is a free measurement on any instrument that already has the detector.

racemisation_ala30 Apr 2024

Epimerisation during activation produces a diastereomer that is mass-identical and only chromatographically separable. At this gradient length the separation exists, and 99.53 % is net of it.

label_claim30 Apr 2024

A retail vial is also a test of the label. Declared claim 0.1 mg against what the gravimetry recovers is a question only a purchased vial can answer honestly.

Section 7

Related records

Same batch — lot SSA-2403-F6772 n=11

Report	Lot	Lab	Quarter	Purity %	Water %	Recovery %	Provenance	Flags	Result
AX-2024-005080	SSA-2403-F6772	Janoshik	2024-Q2	99.06	4.31	99.0	Buyer-sourced	0	PASS
AX-2024-005081	SSA-2403-F6772	Janoshik	2024-Q2	99.12	3.35	100.0	Laboratory-retained	0	PASS
AX-2024-005082	SSA-2403-F6772	PeptideMeter	2024-Q2	99.71	3.76	109.0	Supplier-supplied	0	PASS
AX-2024-005083	SSA-2403-F6772	Medutest	2024-Q2	99.00	4.02	98.0	Buyer-sourced	0	PASS
AX-2024-005084	SSA-2403-F6772	Janoshik	2024-Q2	98.51	4.17	98.0	Buyer-sourced	0	PASS
AX-2024-005085	SSA-2403-F6772	Medutest	2024-Q2	99.54	4.10	—	Buyer-sourced	0	PASS
AX-2024-005087	SSA-2403-F6772	PeptideMeter	2024-Q2	99.67	4.18	99.0	Buyer-sourced	0	PASS
AX-2024-005088	SSA-2403-F6772	PeptideMeter	2024-Q2	99.17	3.40	109.0	Supplier-supplied	0	PASS
AX-2024-005089	SSA-2403-F6772	Medutest	2024-Q2	99.50	3.94	89.0	Supplier-supplied	1	MARGINAL
AX-2024-005090	SSA-2403-F6772	Janoshik	2024-Q2	99.19	3.54	—	Buyer-sourced	0	PASS

Batch rollup and reproducibility assessment →

Cross-sections

Other recent IGF-1 DES (1-3) records in the index.
Report	Supplier	Lot	Lab	Quarter	Purity %	Water %	Recovery %	Provenance	Flags	Result
AX-2026-042672	SWB	SWB-2601-Y8497	Nordanalyt	2026-Q2	98.22	4.32	97.0	Buyer-sourced	1	FAIL
AX-2025-020588	SSA	SSA-2509-Y7224	Janoshik	2025-Q4	97.77	6.23	101.0	Buyer-sourced	0	PASS
AX-2025-020590	SSA	SSA-2509-Y7224	Janoshik	2025-Q4	97.45	6.55	—	Buyer-sourced	0	PASS
AX-2025-020589	SSA	SSA-2509-Y7224	Janoshik	2025-Q4	98.07	6.48	—	Buyer-sourced	0	PASS
AX-2024-005084	SSA	SSA-2403-F6772	Janoshik	2024-Q2	98.51	4.17	98.0	Buyer-sourced	0	PASS
AX-2024-005080	SSA	SSA-2403-F6772	Janoshik	2024-Q2	99.06	4.31	99.0	Buyer-sourced	0	PASS
AX-2024-005081	SSA	SSA-2403-F6772	Janoshik	2024-Q2	99.12	3.35	100.0	Laboratory-retained	0	PASS
AX-2024-005087	SSA	SSA-2403-F6772	PeptideMeter	2024-Q2	99.67	4.18	99.0	Buyer-sourced	0	PASS

Other recent SSA records in the index.
Report	Compound	Lot	Lab	Quarter	Purity %	Water %	Recovery %	Provenance	Flags	Result
AX-2026-043135	BPC-157	SSA-2601-N6863	Nordanalyt	2026-Q2	98.16	4.66	92.8	Buyer-sourced	1	MARGINAL
AX-2026-043160	GHK-Cu	SSA-2604-V7731	Janoshik	2026-Q2	98.01	4.02	91.8	Buyer-sourced	0	PASS
AX-2026-043157	GHK-Cu	SSA-2604-V7731	Medutest	2026-Q2	99.19	5.14	—	Supplier-supplied	0	PASS
AX-2026-043141	BPC-157	SSA-2601-N6863	Janoshik	2026-Q2	98.06	4.06	94.6	Buyer-sourced	1	MARGINAL
AX-2026-043154	GHK-Cu	SSA-2604-V7731	PeptideMeter	2026-Q2	97.82	4.82	101.6	Buyer-sourced	0	PASS
AX-2026-043137	BPC-157	SSA-2601-N6863	PeptideMeter	2026-Q2	98.17	4.14	—	Buyer-sourced	1	MARGINAL
AX-2026-043162	GHK-Cu	SSA-2604-V7731	Janoshik	2026-Q2	98.50	4.36	—	Supplier-supplied	0	PASS
AX-2026-043134	BPC-157	SSA-2601-N6863	Medutest	2026-Q2	97.89	4.01	—	Buyer-sourced	1	FAIL